Tregs

DIAGNOSTIC_TEST2 trials

Sponsors

Poltreg S.A., Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Conditions

Presymptomatic diabetes type 1 (stage 1)VITILIGO

Phase 2

A multicenter, randomized, blinded, placebo controlled, phase II study to evaluate the safety and efficacy of cell therapy based with artificially expanded CD4+CD25+CD127- regulatory lymphocytes and anti-CD20 antibody in pediatric patients with presymptomatic diabetes type 1 (stage 1)

RecruitingCTIS2023-505226-33-00

Poltreg S.A.Presymptomatic diabetes type 1 (stage 1)

Start: 2025-01-28Target: 150Updated: 2025-08-01

Unknown Phase

Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo

CompletedNCT03249064

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauVITILIGO

Start: 2015-10-27End: 2016-09-13Updated: 2017-08-22